Table 2.
Disease characteristics of the SABINA III population included in the analysis (N = 4556) categorized by SABA prescriptions and SABA OTC purchase.
| SABA prescriptions onlya (n = 3449) | SABA prescriptions + SABA OTC purchase (n = 1107) | SABA prescriptions (with and without SABA OTC purchase) (N = 4556) | |
|---|---|---|---|
| Asthma duration (years) | |||
| Mean (SD) | 17.5 (15.40) | 16.6 (13.20) | 17.3 (14.90) |
| Median (Min, Max) | 12.0 (1.0, 85.0) | 13.0 (1.0, 70.0) | 12.0 (1.0, 85.0) |
| 25th and 75th percentile | 6.0, 25.0 | 6.0, 24.0 | 6.0, 25.0 |
| Total | 3449 | 1107 | 4556 |
| GINA classification | |||
| Step 1 | 301 (8.7) | 126 (11.4) | 427 (9.4) |
| Step 2 | 714 (20.7) | 212 (19.2) | 926 (20.3) |
| Step 3 | 781 (22.6) | 220 (19.9) | 1001 (22.0) |
| Step 4 | 1136 (32.9) | 351 (31.7) | 1487 (32.6) |
| Step 5 | 517 (15.0) | 198 (17.9) | 715 (15.7) |
| Total | 3449 | 1107 | 4556 |
| Number of comorbidities | |||
| No comorbidities | 1157 (33.5) | 424 (38.3) | 1581 (34.7) |
| 1–2 comorbidities | 1643 (47.6) | 504 (45.5) | 2147 (47.1) |
| 3–4 comorbidities | 535 (15.5) | 153 (13.8) | 688 (15.1) |
| ≥5 comorbidities | 114 (3.3) | 26 (2.3) | 140 (3.1) |
| Total | 3449 | 1107 | 4556 |
Data are presented as n (%) unless otherwise specified.
GINA Global Initiative for Asthma, Max maximum, Min minimum, OTC over-the-counter, SABA short-acting β2-agonist, SABINA SABA use IN Asthma, SD standard deviation.
aSABA prescriptions only do not include SABA OTC purchase.